DekaBank Deutsche Girozentrale’s Aimmune Therapeutics AIMT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-24,800	Closed	-$494K	–	1170
2019 Q2	$494K	Buy	24,800 +9,700	+64%	+$200K	﹤0.01%	923
2019 Q1	$423K	Buy	15,100 +2,700	+22%	+$63.6K	﹤0.01%	936
2018 Q4	$286K	Sell	12,400 -2,700	-18%	-$69.9K	﹤0.01%	918
2018 Q3	$423K	Sell	15,100 -400	-3%	-$11.3K	﹤0.01%	958
2018 Q2	$424K	Hold	15,500	–	–	﹤0.01%	940
2018 Q1	$495K	Sell	15,500 -300	-2%	-$10.6K	﹤0.01%	872
2017 Q4	$310K	Hold	15,800	–	–	﹤0.01%	897
2017 Q3	$310K	Hold	15,800	–	–	﹤0.01%	903
2017 Q2	$333K	Buy	+15,800	New	+$301K	﹤0.01%	889

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DekaBank Deutsche Girozentrale's AIMT Position: Q3 2019 in Review

DekaBank Deutsche Girozentrale sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 24,800 shares — an estimated $494K sold.

DekaBank Deutsche Girozentrale first reported a position in AIMT in Q2 2017 and held it in 9 quarters. The position peaked at $495K in Q1 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

DekaBank Deutsche Girozentrale reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 24,800 Aimmune Therapeutics shares in Q3 2019, an estimated $494K.
DekaBank Deutsche Girozentrale first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 9 quarters.
DekaBank Deutsche Girozentrale's Aimmune Therapeutics position peaked at $495K in Q1 2018.
146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2019, filed 14 Nov 2019.